Cybear Announces a National Agreement With DIANON Systems for Web Based Laboratory Ordering and Results Delivery.

Business Editors/Health & Medical Writers

BOCA RATON, Fla.--(BUSINESS WIRE)--Jan. 8, 2001

Andrx Corporation - Cybear Group (Nasdaq:CYBA) announced today that is has executed an agreement to provide its Dr. Chart system and other Internet applications to DIANON Systems, Inc. thereby enabling DIANON customers to submit lab orders and to access their lab results through the Cybear physician portal. DIANON currently provides specialized diagnostic testing services to more than 12,000 physicians involved in the diagnosis and treatment of cancer (surgeons and oncologists), and Cybear has agreed to customize its portal and Dr. Chart application for DIANON to enhance their cancer and genomic diagnostic testing services.

Cybear President and COO Timothy Nolan said, "We are excited to have DIANON Systems as a Cybear client. This agreement demonstrates Cybear's commitment to the laboratory market and the continued value of the Dr. Chart product. We are pleased that DIANON has recognized Cybear's leadership in this important sector of our market space."

Andrx Corporation - Cybear Group stock tracks the business of Cybear, Inc., which is headquartered in Boca Raton, Florida, and is an Internet Service Provider (ISP) and Applications Service Provider (ASP) for the healthcare industry. Cybear uses its own secure private network to provide access to the Internet, email, and productivity applications available on a transaction or subscription basis to physicians, physician organizations, pharmacies, and hospitals. More information and subscriptions to dr.cybear and rx.cybear, Cybear's Internet products, are available online at www.cybear.com or by calling 877-999-3001.

DIANON Systems, Inc. provides a full line of anatomic and molecular pathology testing services. The company has laboratories in Connecticut, New York, Florida, and Colorado, and a specimen-processing center in Ohio. The company anticipates that it will diagnose the largest percentage of prostate cancer cases this year in the U.S., nearly ten percent of the nation's new cases. The company is rapidly achieving similar results in other surgical markets for both solid and non-solid tumors. The company also provides the CarePath (TM) Health Information Service, which provides personalized, diagnosis-specific information to physicians and to their patients at critical moments in the health care process.

This press release contains forward-looking information regarding Cybear Inc. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenue and expenses, anticipated transactions, planned product development and products or service line growth, may be significantly impacted by certain risks and uncertainties, including, but not limited to, failure of the clinical e-commerce industry to develop at anticipated rates, failure of the company's clinical information technology products and services and planned products to gain significant market acceptance, contracts not materializing, delays in customer acceptance of Cybear technology, competition and other economic factors. These forward-looking statements speak only as of the date hereof, and Cybear disclaims any intention or obligations to update its forward-looking statements in the future. Additional risks and uncertainties are described in the documents filed by Cybear with the United States Securities and Exchange Commission (the "SEC").